<DOC>
	<DOC>NCT00938301</DOC>
	<brief_summary>The purpose of this first in human (FIH) study is to investigate the safety, tolerability, pharmacokinetics ( how the body handles the drug) and pharmacodynamics (how the drug affects the body) of PF-04455242-01 in healthy adult volunteers.</brief_summary>
	<brief_title>A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Healthy male and/or female of nonchildbearing potential between the ages of 18 and 55 years. Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight &gt;50 kg (&gt;110 lbs). Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures. Evidence or history of clinically significant medical condition or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of screening). Use of tobacco or nicotinecontaining products within 3 months of screening or a positive urine or blood cotinine at screening. A positive urine drug screen. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>healthy volunteer, first in human, safety and tolerability</keyword>
</DOC>